Minzhen Xu
Plus aucun poste en cours
Fortune : 436 000 $ au 30/04/2024
Profil
Minzhen Xu worked as a Vice President at NuGenerex Immuno-Oncology, Inc.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 27/09/2023 | 400 000 ( 5,95% ) | 436 000 $ | 30/04/2024 |
Anciens postes connus de Minzhen Xu
| Sociétés | Poste | Fin |
|---|---|---|
| NUGENEREX IMMUNO-ONCOLOGY, INC. | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Sociétés liées
| Entreprise privées | 1 |
|---|---|
NuGenerex Immuno-Oncology, Inc.
 NuGenerex Immuno-Oncology, Inc. BiotechnologyHealth Technology NuGenerex Immuno-Oncology, Inc. is an oncology company focuses on the modulation of the immune system to treat cancer. It develops immunotherapeutic products and vaccines based on proprietary, patented platform technology, Ii-Key. The Ii-Key is a peptide derived from the major histocompatibility complex (MHC) class II associated invariant chain that regulates the formation, trafficking, and antigen-presenting functions of MHC class II complexes, essential for the activation of T cells in the immune response. The company was founded on October 8, 1993 and is headquartered in Miramar, FL. | Health Technology |
